New Releases from NCBI BookshelfRipretinib (Qinlock): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with advanced gastrointestinal stromal tumour who have received prior treatment with imatinib, sunitinib, and regorafenib [Internet].​Ripretinib (Qinlock): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with advanced gastrointestinal stromal tumour who have received prior treatment with imatinib, sunitinib, and regorafenib [Internet].